Related Experiment Video
Updated: May 2, 2026
Profiling of Pre-micro RNAs and microRNAs using Quantitative Real-time PCR qPCR Arrays
Published on: December 3, 2010
Profiling of MicroRNAs for the Identification of Unique and Common MicroRNAs in Preeclamptic Patients of South India
Vinaya Vijayan1, Kannan Rajendran2, Aparajita D'souza3
1Department of Physiology, Saveetha Institute of Medical And Technical Sciences (SIMATS), Tiruvallur, IND.
Introduction:
Preeclampsia (PE) is a serious pregnancy complication with an unclear cause. Recent studies suggest that microRNAs (miRNAs), particularly miR-1, may play a role in controlling the genes associated with this condition. This study aimed to compare the expression of miRNAs in the blood and placental tissues of women with PE to those with normal pregnancies.
Methods:
We conducted small RNA sequencing on blood and placental samples from three groups: (a) early-onset preeclampsia (EOPE), (b) late-onset preeclampsia (LOPE), and (c) normal pregnancies. Bioinformatics tools were used to compare the miRNA profiles across these groups. A total of 744 miRNAs were detected in placental samples, while 913 miRNAs were found in blood samples. We further analyzed the target genes using protein-protein interaction (PPI) maps to understand how these miRNAs may influence gene functions.
Results:
Our analysis revealed significant differences in miRNA expression between the EOPE, LOPE, and control groups. Eight miRNAs were consistently detected in both blood and placental samples across all groups, while other miRNAs were either specific to PE or certain tissue types. The 492 target genes identified formed dense interaction networks, with several key genes occupying central roles.
Conclusion:
These findings suggest that altered miRNA expression and the resulting disruption of gene networks may contribute to the development of PE. The distinct differences between EOPE and LOPE indicate that these two subtypes may be driven by different underlying mechanisms. This paves the way for future research to explore new treatments targeting these miRNAs and their associated genes.
Insights
Altered microRNA (miRNA) expression in blood and placental tissues is linked to preeclampsia (PE). Differences observed between early-onset and late-onset PE suggest distinct underlying mechanisms, offering potential new therapeutic targets.
Area of Science:
- Obstetrics and Gynecology
- Molecular Biology
- Genetics
Background:
- Preeclampsia (PE) is a significant pregnancy complication with largely unknown etiology.
- MicroRNAs (miRNAs), including miR-1, are implicated in regulating genes potentially involved in PE pathogenesis.
- Understanding miRNA expression in PE is crucial for identifying disease mechanisms.
Purpose of the Study:
- To compare miRNA expression profiles in blood and placental tissues between women with preeclampsia and those with normal pregnancies.
- To investigate potential differences in miRNA expression between early-onset PE (EOPE) and late-onset PE (LOPE).
- To identify key genes and pathways affected by altered miRNA expression in PE.
Main Methods:
- Small RNA sequencing was performed on blood and placental samples from EOPE, LOPE, and control groups.
- Bioinformatic analyses were used to compare miRNA expression patterns across the groups.
- Protein-protein interaction (PPI) networks were constructed to analyze target genes of differentially expressed miRNAs.
Main Results:
- Significant differences in miRNA expression were observed between PE subtypes and controls in both blood and placental tissues.
- Eight miRNAs were commonly detected across all samples, while others showed tissue- or condition-specific expression.
- Analysis of 492 target genes revealed complex interaction networks with several central regulatory genes.
Conclusions:
- Altered miRNA expression and subsequent gene network dysregulation are likely contributors to PE development.
- Distinct miRNA profiles in EOPE and LOPE suggest different etiological pathways for these subtypes.
- These findings provide a basis for developing novel miRNA-targeted therapies for preeclampsia.
